These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 37743207

  • 1. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L, Cruz-Cañete M, Pérez C, Couceiro JA, Otheo E, Launes C, Rodrigo C, Jiménez AB, Llorente M, Montesdeoca A, Rumbao J, Calvo C, Frago S, Tagarro A.
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [Abstract] [Full Text] [Related]

  • 2. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, Rameix-Welti MA, White M, Baudemont G, Lina B, Parent du Châtelet I, Casalegno JS, Vaux S, Cauchemez S.
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T.
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [Abstract] [Full Text] [Related]

  • 4. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP, Nirsevimab Study Group.
    N Engl J Med; 2020 Jul 30; 383(5):415-425. PubMed ID: 32726528
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM.
    Nurs Womens Health; 2024 Feb 30; 28(1):75-79. PubMed ID: 38070539
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, Malvar-Pintos A, González-Pérez JM, Rodríguez-Tenreiro-Sánchez C, Rivero-Calle I, Salas A, Durán-Parrondo C, Martinón-Torres F, NIRSE-GAL study group.
    Lancet Infect Dis; 2024 Aug 30; 24(8):817-828. PubMed ID: 38701823
    [Abstract] [Full Text] [Related]

  • 8. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR, New Vaccine Surveillance Network Product Effectiveness Collaborators, McMorrow ML, Dawood FS.
    MMWR Morb Mortal Wkly Rep; 2024 Mar 07; 73(9):209-214. PubMed ID: 38457312
    [Abstract] [Full Text] [Related]

  • 9. What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.
    Debessai H, Jones JM, Meaney-Delman D, Rasmussen SA.
    Obstet Gynecol; 2024 Mar 01; 143(3):e54-e62. PubMed ID: 38061043
    [Abstract] [Full Text] [Related]

  • 10. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C, Lockowitz CR, Newland JG.
    Neonatal Netw; 2024 Apr 01; 43(2):105-115. PubMed ID: 38599778
    [Abstract] [Full Text] [Related]

  • 11. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC, Tripp RA.
    Expert Opin Investig Drugs; 2022 Jan 01; 31(1):23-29. PubMed ID: 34937485
    [Abstract] [Full Text] [Related]

  • 12. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
    Mallah N, Ares-Gómez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Pérez MI, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, González-Pérez JM, Rodríguez-Tenreiro C, Rivero-Calle I, Salas A, Durán-Parrondo C, Martinón-Torres F.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2348135. PubMed ID: 38738683
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France.
    Carbajal R, Boelle PY, Pham A, Chazette Y, Schellenberger M, Weil C, Colas AS, Lecarpentier T, Schnuriger A, Guedj R, Lorrot M, Corvol H, Enault M.
    Lancet Child Adolesc Health; 2024 Oct 31; 8(10):730-739. PubMed ID: 39208832
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
    Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN, HARMONIE Study Group.
    N Engl J Med; 2023 Dec 28; 389(26):2425-2435. PubMed ID: 38157500
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.